Stroke Clinical Trial
Official title:
Evaluation of the Safety and Performance of the Zenith LAA Occlusion System and Procedure for the Mechanical Closure of the Left Atrial Appendage (LAA)
NCT number | NCT05951101 |
Other study ID # | CLN002 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | February 28, 2024 |
Est. completion date | July 31, 2025 |
Demonstrate the safety and performance of the Zenith LAA Occlusion System and procedure to occlude the Left Atrial Appendage (LAA) from the left atrium (LA) using a minimally invasive technique. Indication - LAA closure in patients with non-valvular atrial fibrillation, with an ostial diameter between 18 mm and 26 mm
Status | Recruiting |
Enrollment | 10 |
Est. completion date | July 31, 2025 |
Est. primary completion date | May 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Age =18 and =80 years at the time of screening 2. Documented diagnosis of non-valvular AF 3. Clinical indication for LAA occlusion 4. Willing and able to return to and comply with scheduled follow-up visits and testing, including medical treatment as required by the protocol. 5. Willing and able to provide written informed consent Exclusion Criteria: Within 30 days before the procedure date: 1. Exhibited NYHA class III or IV heart failure symptoms 2. Known bleeding disorders (such as bleeding diathesis, thrombocytopenia [platelet count <100 X 109/L], severe anaemia [haemoglobin of <8 g/dL], or INR >2 [spontaneous]) Within 90 days before the procedure date: 3. Documented history of myocardial infarction or unstable angina 4. Documented embolic stroke, TIA or suspected neurologic event 5. Chronic renal insufficiency (eGFR =15mL/min per 1.73 m2 (CKD-EPI)) or end-stage renal disease 6. Requires long-term oral anticoagulation therapy for a condition other than AF 7. Diagnosed active local or systemic infection, septicaemia, active pericarditis, or fever of unknown origin 8. Known acquired or inherited propensity for forming blood clots (e.g., malignancy and factor V Leiden mutation) established by prior objective testing 9. Contraindication to the standard of care post-implantation antithrombotic medication regime (e.g., dual antiplatelet therapy (DAPT)/direct oral anticoagulant (DOAC) 10. Rheumatic heart disease 11. Implanted mechanical valve prosthesis 12. Documented carotid disease, defined as greater than 70% stenosis without symptoms or greater than 50% stenosis with symptoms 13. Body mass index greater than 40 kg/m2 14. Patient is pregnant or breastfeeding or plans/desires to get pregnant within the next 12 months post-procedure 15. Current or planned enrolment in an investigation or study of an investigational device or investigational drug that would interfere with this study and the required follow-up 16. Mental impairment or other psychiatric conditions which may not allow the patient to understand the nature, significance, and scope of the study 17. Any other criteria (including physical and mental health), medical illness, or comorbidity which would make the subject unsuitable to participate in this study as determined by the clinical site principal investigator 18. Patients with known allergy or sensitivity to nitinol (nickel and titanium) or any of the other materials in the Zenith LAA Occlusion System Implant 19. Life expectancy of less than 1 year 20. Inability, unwillingness, or contraindication to undergo Trans-Oesophageal and/or Trans-Thoracic Echocardiogram (TOE/TTE) or Cardiac Computed Tomography Angiography (CCTA) imaging or any catheterisation procedures 21. Any anatomical condition that precludes the patient from undergoing LAA occlusion with the AuriGen Zenith LAA Occlusion System implant procedure, as determined by the principal investigator Imaging Exclusion Criteria: 22. Patients with a maximal ostial left atrial appendage diameter >25 mm or <17 mm by pre-procedural ECG-gated CT scan, to fit the Zenith LAA Occlusion System 23. Patients where CCTA analysis suggests that the Zenith LAA Occlusion System may not be suitable 24. Intracardiac thrombus diagnosed by CCTA or echocardiography 25. Previous occlusion/ligation of the LAA (by any surgical or percutaneous method) 26. Documented presence of implanted closure devices (e.g. Atrial septal defect (ASD), Patent foramen ovale (PFO) or Ventricular septal defect (VSD) device) for congenital defect treatment 27. Documented Left Ventricular Ejection Fraction (LVEF) <30% |
Country | Name | City | State |
---|---|---|---|
New Zealand | Auckland City Hospital | Auckland | |
New Zealand | Christchurch Hospital | Christchurch |
Lead Sponsor | Collaborator |
---|---|
AuriGen Medical Ltd |
New Zealand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Procedural success | Acute procedural success is defined as the delivery and release of the Zenith LAA Occlusion System in the target location (LAA) without any device or procedure related serious adverse events until the post-procedure discharge or 72 hours (whichever comes first) | 72 hours | |
Primary | Mechanical device closure | Mechanical device closure - residual jet around the device =5 mm at 45 days by TOE | 45 days | |
Secondary | Device related thrombus | LAAO device-related thrombus as assessed by TOE at 45 days and by CCTA at 12 months | 45 days and 12 months | |
Secondary | SAE | All SAEs device and/or procedure-related post-procedure and to the end of the study | through study completion, an average of 1 year | |
Secondary | Stroke | Ischemic stroke through 12 months | 12 months | |
Secondary | Thromboembolism | Systemic thromboembolism through 12 months | 12 months | |
Secondary | Device closure | Mechanical device closure - residual jet around the device =5 mm at 6 months (if it is not achieved at 45 Days) | 6 months | |
Secondary | Device use questionnaire | Use of the Zenith LAA Occlusion System per Device use questionnaire (Operator) | up to 24 hours | |
Secondary | Changes in Quality of Life score according to SF-12 questionnaire | Patient-reported health quality at Baseline, 45 days, 6 months, and 12 months | Baseline, 45 days, 6 months and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Recruiting |
NCT03869138 -
Alternative Therapies for Improving Physical Function in Individuals With Stroke
|
N/A | |
Completed |
NCT04101695 -
Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects
|
N/A | |
Completed |
NCT04034069 -
Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Completed |
NCT00391378 -
Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS)
|
N/A | |
Recruiting |
NCT06204744 -
Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial
|
N/A | |
Active, not recruiting |
NCT06043167 -
Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
|
||
Active, not recruiting |
NCT04535479 -
Dry Needling for Spasticity in Stroke
|
N/A | |
Completed |
NCT03985761 -
Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke
|
N/A | |
Recruiting |
NCT00859885 -
International PFO Consortium
|
N/A | |
Recruiting |
NCT06034119 -
Effects of Voluntary Adjustments During Walking in Participants Post-stroke
|
N/A | |
Completed |
NCT03622411 -
Tablet-based Aphasia Therapy in the Chronic Phase
|
N/A | |
Completed |
NCT01662960 -
Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke
|
N/A | |
Recruiting |
NCT05854485 -
Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke
|
N/A | |
Active, not recruiting |
NCT05520528 -
Impact of Group Participation on Adults With Aphasia
|
N/A | |
Completed |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Completed |
NCT05805748 -
Serious Game Therapy in Neglect Patients
|
N/A | |
Recruiting |
NCT05993221 -
Deconstructing Post Stroke Hemiparesis
|